IDM Pharma, Inc., a biopharmaceutical company, engages in the development of products to treat and control cancer. It develops product candidates to destroy residual cancer cells and to stimulate an immune response and prevent tumor recurrence. The company’s products include L-MTP-PE/MEPACT, a Phase 3 clinical trial completed liposomal muramyl-tripeptide phosphatidylethanol- amine, for the treatment of osteosarcoma; BEXIDEM, a Phase 2 clinical trial completed product for the treatment of bladder cancer; UVIDEM, a Phase 2 clinical trial dendritophage and melanoma tumor cell lysates product, for the treatment of melanoma; IDM-2101, a multiple tumor-associated CTL epitopes Phase 2 clinical trial product, for the treatment of non-small cell lung cancer; and COLLIDEM, a Phase 1/2 dendritophages and tumor associated antigen peptides product, for the treatment of colorectal cancer. It has operations in the United States and France. IDM Pharma has collaboration agreements with sanofi-aventis S.A; Medarex, Inc.; GenPharm International, Inc.; Novartis; and Biotecnol S.A. It also has intellectual property licensing and framework agreement with Institut de Recherche Pierre Fabre and Pierre Fabre Médicament S.A. The company was incorporated in 1987 and is based in Irvine, California.
$1.98 (03/31/09)
